test pellets

Testosterone is a hormone that exists in both men and women, but the amounts each sex needs are dramatically different, and that gap is at the center of why certain delivery methods that work well for men can become genuinely dangerous for women. The normal reference range for testosterone in women sits somewhere between 15 and 70 nanograms per deciliter, which is a unit of measurement that describes how much of a substance is floating around in a set volume of blood. For men, the average hovers around 500 nanograms per deciliter, and many physicians who work in this space argue that men don't really feel or perform at their best until that number climbs above 800 or even 1,000.

That difference in scale matters enormously when you start talking about something called pellet therapy, which is a method of hormone delivery where a small compressed pellet of testosterone gets inserted under the skin, usually near the hip or buttocks, and slowly dissolves over several months. The appeal for men is obvious because it removes the daily or weekly routine of injections, creams, or patches, and the body gets a slow and relatively steady release of hormone without the person having to think about it. For men, this set-and-forget quality works in their favor because even if the dose is slightly off, the physiological range is wide enough that small errors don't tend to produce catastrophic outcomes.

Women don't have that same cushion. Because the female reference range tops out at 70 nanograms per deciliter, a pellet that delivers even a modest miscalculation in dose can push a woman's testosterone levels to 20 or even 50 times what her body is supposed to have. This isn't a hypothetical edge case. It is a real risk that comes from the simple arithmetic of how narrow the female range is compared to the male range, and how much testosterone a typical pellet is designed to release over its lifespan.

The part that makes this especially serious is something called irreversibility, which means that once certain biological changes happen in the body from elevated testosterone exposure, they don't simply go away when the hormone returns to normal. Voice deepening is one of the most well-documented examples of this. When a woman is exposed to high androgens, which is the technical category of hormones that testosterone belongs to, for a long enough period, the larynx can undergo structural changes that lower the pitch of the voice permanently. Reducing the testosterone after the fact does not undo what already happened to the tissue.

With a pellet already under the skin, there is no straightforward way to turn off the hormone delivery if something goes wrong. A cream can be stopped. An injection wears off over days. A pellet continues dissolving and releasing testosterone into the bloodstream for months regardless of what the patient or doctor wants. This means that if a woman receives a pellet and her levels come back far too high on a follow-up blood test, she and her doctor are essentially waiting out a slow clock while the exposure continues.

Other side effects that come from elevated androgens in women include things like increased body hair growth in places typically associated with male patterns, acne, changes in the clitoris, and disruptions to the menstrual cycle. Some of these effects fade when testosterone returns to normal range, but others, like the voice changes, can persist long after the hormone levels do. The duration of exposure plays a significant role in how permanent the outcome ends up being, which is part of why the slow-release nature of pellets is the specific problem here and not testosterone supplementation in women more broadly.

Testosterone therapy in women is not inherently wrong or dangerous when done correctly because there are legitimate reasons a physician might want to raise a woman's testosterone slightly, including low libido, fatigue, and certain hormonal deficiencies that can come with age or with conditions affecting the ovaries. The method of delivery and the precision of dosing are what determine whether that therapy is safe or reckless. Injectable or topical forms of testosterone give the prescribing physician the ability to adjust, pause, or stop treatment quickly if the patient's levels come back outside of the intended window.

Something called bioidentical hormone therapy, which is a broader category of hormone treatments that use compounds designed to be chemically identical to what the human body naturally produces, includes pellets as one possible delivery format among several. Advocates of pellet therapy often point to its convenience and the stability of hormone levels it can provide, but those arguments apply most cleanly to men, whose biology tolerates the reduced precision that comes with a device that cannot be titrated once it is implanted.

The reference range disparity also makes dosing for women a much more technically demanding task than dosing for men. A physician prescribing testosterone pellets for a man is working with a target zone that spans hundreds of nanograms per deciliter. A physician trying to do the same for a woman is working with a zone that spans roughly 55 nanograms per deciliter at its widest, and a pellet that overshoots by what might seem like a small margin in absolute terms can represent a multiple of the entire intended range. That kind of math leaves almost no room for the natural variation in how quickly different people absorb and metabolize hormones, and those individual differences are real and significant.

Hormone pellets became popular in part because of the genuine inconvenience of other delivery methods, and the wellness and anti-aging industry has embraced them as a premium, low-maintenance option. But the inconvenience of other delivery methods is exactly the feature that makes them safer for women. The ability to stop, adjust, and correct in real time is not a limitation of those methods. It is a safeguard, and it is one that pellets by design cannot offer. Women considering testosterone therapy deserve to understand that the convenience being sold with pellet therapy comes at the cost of the flexibility that would protect them if something goes wrong.

References

1. Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc. 2004. Source
2. Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J Clin Endocrinol Metab. 1998. Source
3. Turner JW Jr. Effects of sustained-release testosterone on marking behavior in the Mongolian gerbil. Physiol Behav. 1979. Source
4. Becker RR, Gunsalus GL, Musto NA et al.. The epididymis contributes minimally to serum androgen-binding protein in the rat: a whole body kinetic study. Endocrinology. 1984. Source
5. Jasuja R, Pencina KM, Spencer DJ et al.. Reference intervals for free testosterone in adult men measured using a standardized equilibrium dialysis procedure. Andrology. 2023. Source
6. Sepich M, Bertelloni S, Tyutyusheva N et al.. Gonadal Function and Its Evolution in 46,XX Testicular/Ovotesticular DSD. J Clin Endocrinol Metab. 2026. Source
7. Moran LJ, Hutchison SK, Norman RJ et al.. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011. Source

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness